Clinical Efficacy and Safety of Mildronate in Patients with Ischemic Heart Disease and Chronic Heart Failure

Kardiologiya

Volumn 40, Issue 6, 2000, Pages 69-74

  Karpov, R S ^a   Koshelskaya, O A ^a   Vrublevsky, A V ^a   Sokolov, A A ^a   Teplyakov, A T ^a   Skarda, I ^a   Dzerve, V ^a   Klintsare, D ^a   Vitols, A ^a   Kalninsh, U ^a   Kalvinsh, I ^a   Matveya, L ^a   Urbane, D ^a  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

Author keywords

Contractility; Heart failure; Left ventricle; Mildronate; Physical working capacity; Treatment

Indexed keywords

EID: 0011158679     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Simkhovitch B., Shutenko Z., Meirena D. et al. 3-(2,2,2-Trimethylhydrazinium)propionate (THR) - a novel γ-butirobetaine hydroxylase inhibitor with cardioprotective properties. Biohem Pharmacol 1989;31:195-202.
2. Asaka N., Muranaka Y., Hayashi Y. et al. Cardioprotective profile of MET-88 in isolated perfused rat hearts. Eur Heart J 1994;15:Suppl 595:93.
3. Kirimoto T., Nobori K., Asaka N. et al. Beneficial Effect of MET-88, a γ-butirobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch international Pharmacodyn Therapie 1996;331:163-177.
4. Dhar P.K., Grupp I.L., Schwartz A. et al. Reduction of carnitine content by inhibition of its biosynthesis results in protection of isolated guinea pig hearts againts hypoxic damage. J Cardiovasc Pharmacol Therap 1996;1:235-242.
5. Skarda I., Dzerve V., Klincare D. et al. Mildronate - a new drug for treatment of chronic heart failure. Scandinavian Cardiovasc J 1997;31:Suppl 45:22.